Slide 1: Second Quarter 2023 Operating & Financial Results Conference Call
Second Quarter 2023 Operating & Financial Results Conference Call / Webinar August 9th, 2023 4:30 PM Eastern Time NASDAQ: LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents and Speakers
Contents Speakers Host Panna Sharma David Margrave Nicole Leber 01 Introduction CEO and President CFO Investor Relations 02 Q2 2023 Highlights 03 Financial Highlights 04 Q&A
Slide 4: Lantern is Transforming Drug Discovery Timelines & Costs with AI
Lantern is Transforming Drug Discovery Timelines & Costs with AI AI insights and Lantern can compress the biomarkers can increase timeline of early-stage drug the odds of clinical trial development by 70% and success by 12X* reduce the cost by 80% RADR® can predict and Lantern has launched 10 new st
Slide 5: Lantern's diverse AI-driven pipeline of drug programs
Lantern’s diverse & unique AI-driven pipeline of 14 drug programs includes the Phase 2 Harmonic™ trial and RADR® collaborations Lantern Pharma (NASDAQ: LTRN) Orphan Rare Pediatric Program Indication Discovery Preclinical Phase I Phase II Designation Disease LP-300 Non-Small Cell Lung Cancer for Neve
Slide 6: 2nd Quarter Highlights 1 of 2
Obtained FDA clearance of the IND application for 2023 • LP-184 and activated initial clinical sites for the Phase 1 basket trial in relapsed/refractory advanced solid tumors 2nd Quarter and brain cancers – a patient population with unmet clinical needs. Highlights • Completed IND-enabling studies f
Slide 7: 2nd Quarter Highlights 2 of 2
2023 2nd Quarter • Initiated RADR® collaboration with Bielefeld Univ. to design and develop breakthrough antibody drug Highlights conjugates (ADCs) with greater precision and efficacy. • Received US Patent & Trademark Office notice of 2of 2 allowance for composition of matter patent for LP-284, extendin
Slide 8: Financial Updates Q2 2023
Financial Updates Q2 2023 Solid financial position and capital efficiency fuel continued growth and give Lantern cash runway into 2025 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended June 30, (unaudited) 06/30/2023 12/31/2022 2023 2022 (unaudited) Operating expens
Slide 9: First-In-Human Trial for LP-184
LP-184: Launched Phase 1 basket trial for a blockbuster molecule with a market potential of $10+ billion in annual sales First-In-Human Trial for LP-184 LP-184 Phase 1A Trial Design June IND application 2023 cleared by FDA Dose Levels 1-4 (n ≥ 3, BOIN*) Clinicaltrials.gov (NCT05933265) Dose Level 5
Slide 10: First-In-Human Trial for LP-284
LP-284: Ph. 1 trial anticipated to launch in Q4 for recurrent NHLs with scarce therapeutic options & market potential of $1+ billion in annual sales First-In-Human Trial for LP-284 Q2 Completed IND Recent Highlights 2023 enabling studies • Received notice of allowance from the USPTO for the composit
Slide 11: Harmonic: Accelerating recruitment efforts for a growing indication
Harmonic™: Accelerating recruitment efforts for a growing indication with limited treatment options and an annual global market potential of $2.5+ bn Annual Market Potential (global) : $2.5+ Billion Trial Updates • Dr. Joseph Treat, MD of Fox Chase Cancer Center: appointed lead principal investigator
Slide 12: ADCs: Initiated RADR collaboration with Bielefeld University
ADCs: Initiated RADR® collaboration w/ Bielefeld Univ. to develop breakthrough cryptophycin ADCs - an entirely new treatment modality Rapidly growing global ADC market • RADR® ADC module will be leveraged to $4+ billion develop novel and potent cryptophycin-ADCs currently valued at • Lantern receive
Slide 13: RADR's expansion of size, scope, and capabilities
RADR®’s expansion of size, scope, and capabilities continues to push the boundary of AI for oncology drug discovery and development SIZE 50 billion oncology- focused datapoints by end of 2023 SCOPE • Additional classes of compounds including antibodies, checkpoint inhibitors, DNA damaging * agents,
Slide 14: 2023-24 Objectives
2023-24 Objectives A Transformational Year for Lantern ● Accelerate enrollment of The Harmonic™ Trial & increase patient/clinician awareness T ● Launch and advance clinical trial(s) for LP-184, including in combination programs O ● Advance first-in-human clinical trial for LP-284 P ● Progress Starli
Slide 15: IR Contact
IR Contact: IR@lanternpharma.com 1-972-277-1136 NASDAQ: LTRN www.lanternpharma.com @LanternPharma Sign up for Newsletter https://lantern-pharma.read.axioshq.com/signup/lantern-pharma-newsletter CONNECT WITH US